文献速递姑息放疗与转移瘤

寡转移性疾病的重复立体定向体部放疗

Repeat stereotactic body radiotherapy for oligometastatic disease.
PubMed 文献 · Radiother Oncol · 2023-04-12

本回顾性研究纳入385例接受立体定向体部放疗(SBRT)治疗1-5个转移灶的寡转移性疾病(OMD)患者,比较单次与重复SBRT的特征和结局。重复SBRT患者无进展生存期(PFS)更短,但广泛失败无生存期(WFFS)和系统性治疗无生存期(STFS)相当,且中位总生存期(OS)更长。作者认为重复SBRT的作用需进一步前瞻性研究。

要点

  • 385例OMD患者中,129例接受重复SBRT,256例接受单次SBRT。
  • 重复SBRT患者PFS更短(p<0.0001),但WFFS(p=0.47)和STFS(p=0.22)与单次SBRT相当。
  • 重复SBRT患者中位OS更长(p=0.01),低远处转移速度和更多既往系统治疗线数显著预测重复SBRT的使用。

核心结论

  • 尽管重复SBRT患者PFS更短、WFFS和STFS与单次SBRT相当,但重复SBRT患者中位OS更长。
  • 重复SBRT在OMD患者中的作用需进一步前瞻性研究,重点在于筛选可能获益患者的预测因素。

研究设计与样本

  • 本回顾性研究纳入接受SBRT治疗1-5个转移灶的OMD患者,分为单次SBRT组和重复SBRT组。
  • 共纳入385例患者,其中129例接受重复SBRT,256例接受单次SBRT。
  • 采用单变量和多变量逻辑回归分析预测重复SBRT使用的患者和治疗特征。

主要发现

  • 两组中最常见的原发肿瘤和OMD状态均为肺癌和异时性寡复发。
  • 重复SBRT患者PFS更短(p<0.0001),而WFFS(p=0.47)和STFS(p=0.22)相当。
  • 重复SBRT患者中远处失败、尤其是单个转移灶的远处失败更常见。
  • 重复SBRT患者中位OS更长(p=0.01)。
  • 多变量逻辑回归显示,低远处转移速度和更多既往系统治疗线数显著预测重复SBRT的使用。

局限性

  • 原文为回顾性研究。
  • 重复SBRT在OMD患者中的作用需进一步前瞻性研究。
  • 需重点研究预测因素以筛选可能获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with oligometastatic disease (OMD) treated with metastasis-directed definitive local therapy such as stereotactic body radiotherapy (SBRT) are at risk of developing new metastases. Here, we compare characteristics and outcomes of patients treated with a single course and repeat SBRT. MATERIALS/METHODS: OMD patients treated with SBRT to 1-5 metastases were included in this retrospective study, and classified as single course or repeat SBRT. Progression-free survival (PFS), widespread failure-free survival (WFFS), overall survival (OS), systemic therapy-free survival (STFS) and cumulative incidence of different first failures were analyzed. Patient and treatment characteristics predicting the use of repeat SBRT were investigated using univariable and multivariable logistic regression. RESULTS: Among the 385 patients included, 129 and 256 received repeat or single course SBRT, respectively. The most common primary tumor and OMD state in both groups were lung cancer and metachronous oligorecurrence. Patients treated with repeat SBRT had shorter PFS (p < 0.0001), while WFFS (p = 0.47) and STFS (p = 0.22) were comparable. Distant failure, particularly with a single metastasis, was more frequently observed in repeat SBRT patients. Repeat SBRT patients had longer median OS (p = 0.01). On multivariable logistic regression, low distant metastases velocity and more previous lines of systemic therapy significantly predicted the use of repeat SBRT. CONCLUSION: Despite shorter PFS and comparable WFFS and STFS, repeat SBRT patients had longer OS. The role of repeat SBRT for OMD patients warrants further prospective investigation, focussing on predictive factors to select patients that might derive a benefit.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Willmann J, Adilovic S, Vlaskou Badra E, et al. Repeat stereotactic body radiotherapy for oligometastatic disease. Radiother Oncol. 2023. PMID: 37059336. doi:10.1016/j.radonc.2023.109671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。